

Igor Puzanov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7086735/igor-puzanov-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225 papers	30,509 citations	60 h-index	174 g-index
251 ext. papers	36,103 ext. citations	8.2 avg, IF	6.6 L-index

#	Paper	IF	Citations
225	Managing Metastatic Melanoma in 2022: A Clinical Review.. <i>JCO Oncology Practice</i> , 2022 , OP2100686	2.3	8
224	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 179	8.5	
223	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 200	8.5	
222	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1692-1704	21.7	23
221	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021 , 19, 64-72	0.1	1
220	Neoadjuvant Pembrolizumab and High-Dose IFN- γ -2b in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4195-4204	12.9	3
219	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021 , 145, 1-10	7.5	5
218	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021 , 11, 1996-2013	24.4	10
217	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021 , 12, 1402	17.4	16
216	The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 144	8.5	
215	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	19.7	24
214	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 142	8.5	1
213	Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2568-2568	2.2	1
212	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis 2021 , 9,		2
211	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 238	8.5	1
210	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58
209	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors 2021 , 9,		2

208	Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. <i>Clinical Cancer Research</i> , 2021 , 27, 87-95	12.9	27
207	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
206	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
205	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3317-3328	12.9	4
204	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2914-2925	2.2	20
203	Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy. <i>American Journal of Cancer Research</i> , 2021 , 11, 5190-5213	4.4	13
202	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020 , 7, MMT41	2.1	2
201	COVID-19 and Cancer: a Comprehensive Review. <i>Current Oncology Reports</i> , 2020 , 22, 53	6.3	147
200	Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab. <i>OncoTargets and Therapy</i> , 2020 , 13, 4021-4034	4.4	3
199	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy 2020 , 8,		45
198	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study 2020 , 8,		28
197	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020 , 10, 657-663	6.3	46
196	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 46-53	12.9	21
195	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. <i>Cancer</i> , 2020 , 126, 3021-3030	6.4	52
194	Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10029-10029	2.2	1
193	Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5080-5080	2.2	1
192	Cardiovascular Toxicities of Immunotherapy 2020 , 259-276		
191	Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 96-96	2.2	

190	Intratumoral Immunotherapy-Update 2019. <i>Oncologist</i> , 2020 , 25, e423-e438	5.7	44
189	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	13.4	27
188	The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019 2020 , 8,		1
187	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1590-1598	8.7	17
186	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5598-5608	12.9	3
185	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020 , 18, 171	8.5	1
184	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. <i>Case Reports in Oncology</i> , 2019 , 12, 260-276	1	41
183	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 2019 , 7, 221		2
182	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
181	The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs. <i>JAMA Dermatology</i> , 2019 , 155, 862-863	5.1	1
180	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. <i>British Journal of Cancer</i> , 2019 , 121, 417-420	8.7	17
179	Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101) 2019 ,		2
178	A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9586-9586	2.2	5
177	Oncologist uptake of comprehensive genomic profile guided targeted therapy. <i>Oncotarget</i> , 2019 , 10, 4616-4629	3.3	8
176	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9524-9524	2.2	2
175	Toxicities in Immune Checkpoint Inhibitors 2019 , 205-226		1
174	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>OncImmunology</i> , 2019 , 8, e1524625	4.25	25
173	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , 2018 , 19, 405-415	21.7	236

172	Oncolytic Viruses: T-VEC and Others 2018 , 387-403		1
171	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. <i>Journal of Translational Medicine</i> , 2018 , 16, 101	8.5	3
170	Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Circulation: Heart Failure</i> , 2018 , 11, e004408	7.6	19
169	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 95-109	5.1	32
168	Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 112-121	3.8	6
167	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018 , 6, 69		10
166	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden 2018 , 6, 32		73
165	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
164	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 742-774	7.3	134
163	A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9515-9515	2.2	13
162	Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN- γ 2b in locally/regionally advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 181-181	2.2	8
161	Comprehensive immune and mutational profile of melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 182-182	2.2	1
160	Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 23-23	2.2	1
159	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 579-579	2.2	10
158	A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS219-TPS219	2.2	1
157	Effect of CTLA-4 overexpression on response to ipilimumab in melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 190-190	2.2	0
156	Correlation of lung cancer mutational profile with immune profile.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 146-146	2.2	0
155	Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS9601-TPS9601	2.2	

154	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
153	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3477-3484	2.2	139
152	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1714-1768	2.2	1740
151	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1658-1667	2.2	357
150	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	14
149	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. <i>Nature Communications</i> , 2018 , 9, 3600	17.4	60
148	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018 , 56, 460-472	4.8	13
147	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma 2017 , 5, 1		37
146	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3601-3609	12.9	42
145	Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017 , 40, 31-35	5	62
144	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy 2017 , 5, 8		86
143	mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. <i>OncoTargets and Therapy</i> , 2017 , 10, 965-971	4.4	20
142	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials 2017 , 5, 72		23
141	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2535-2541	22.2	244
140	Challenges faced when identifying patients for combination immunotherapy. <i>Future Oncology</i> , 2017 , 13, 1607-1618	3.6	7
139	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017 , 170, 1109-1119.e10	56.2	762
138	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017 , 6, 1904-1914	4.8	13
137	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. <i>Melanoma Research</i> , 2017 , 27, 585-590	3.3	14

136	A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 435-442	4.8	7
135	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
134	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2004-2004	2.2	1
133	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9074-9074	2.2	9
132	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9507-9507	2.2	95
131	Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9509-9509	2.2	22
130	Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9566-9566	2.2	4
129	A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14040-e14040	2.2	11
128	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
127	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016 , 7, 10582	17.4	248
126	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction 2016 , 4, 60		46
125	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016 , 375, 1749-1755	59.2	1100
124	Treatment of elderly patients with melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016 , 9, 13-16	0.3	
123	Talimogene laherparepvec in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 781-788	1.1	
122	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2619-26	2.2	359
121	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016 , 23, 4169-4177	3.1	179
120	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 871-8	2.2	206
119	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 378-388	21.7	240

118	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016 , 2, 234-40	13.4	408
117	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 2008-16	4.0	374
116	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 474-480	12.5	14
115	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2	3
114	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 105-105	2.2	9
113	Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5581-5581	2.2	21
112	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9513-9513	2.2	8
111	Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9516-9516	2.2	1
110	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9568-9568	2.2	68
109	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9598-TPS9598	2.2	6
108	Thyroid nodule: not as clear-cut as it seems. <i>Journal of Community and Supportive Oncology</i> , 2016 , 14, 45-8		
107	Comprehensive echocardiographic assessment of cardiac function in patients with metastatic renal cell carcinoma newly initiated on sunitinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16072-e16072	2.2	
106	Risk of left ventricular systolic dysfunction with sunitinib therapy in patients with metastatic renal cell carcinoma: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16104-e16104	2.2	
105	Anti-PD-1 in patients with advanced malignancies and baseline organ dysfunction.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14539-e14539	2.2	
104	Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21023-e21023	2.2	
103	Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 470-3	4.5	15
102	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016 , 4, 569-73	12.5	18
101	Responses to immune checkpoint inhibitors in nonagenarians. <i>OncolImmunology</i> , 2016 , 5, e1234572	7.2	19

100	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 304-313.e6	3.3	10
99	Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 867-873	7	
98	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016 , 67, 46-54	7.5	54
97	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016 , 4, 959-967	12.5	318
96	A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 101-3	4.5	8
95	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>New England Journal of Medicine</i> , 2015 , 373, 428-37	59.2	309
94	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015 , 3, 464-9	12.5	71
93	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015 , 7, 611-9	3.8	98
92	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 908-18	21.7	1151
91	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
90	Treatment of NRAS-mutant melanoma. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 15	5.4	86
89	Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) + the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). <i>Journal of Translational Medicine</i> , 2015 , 13, K8	8.5	23
88	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015 , 113, 1571-80	8.7	76
87	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2015 , 373, 726-36	59.2	1172
86	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 5215-21	12.9	13
85	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1389-403	3.5	70
84	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 159-68	4.3	40
83	Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 611-2	4.5	105

82	Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. <i>Anti-Cancer Drugs</i> , 2015 , 26, 785-924	2.4	2
81	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015 , 51, 1435-43	7.5	52
80	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2780-8	2.2	1480
79	A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 701-11	12.9	73
78	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015 , 126, 4263-4263	2.2	9
77	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3012-3012	2.2	17
76	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3068-3068	2.2	3
75	Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4507-4507	2.2	8
74	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4508-4508	2.2	2
73	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9019-9019	2.2	5
72	Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9020-9020	2.2	11
71	Updated overall survival (OS) results for BRF113220, a phase III study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9036-9036	2.2	12
70	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9040-9040	2.2	2
69	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9063-9063	2.2	22
68	Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20045-e20045	2.2	0
67	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS9081-TPS9081	2.2	8
66	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study 2014 , 2, 2		33
65	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. <i>Oncologist</i> , 2014 , 19, 616-22	5.7	80

64	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. <i>Lancet Oncology, The</i> , 2014 , 15, 954-65	21.7	197
63	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1020-30	2.2	1684
62	Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) 2014 , 2,		13
61	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 2684-93	6.4	79
60	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1744-53	27.4	259
59	A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10503-10503	2.2	7
58	Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2511-2511	2.2	34
57	VE-BASKET, a first-in-kind, phase II, histology-independent Basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2533-2533	2.2	8
56	Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9002-9002	2.2	50
55	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9006-9006	2.2	2
54	Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9008a-9008a	2.2	22
53	Updated overall survival (OS) for BR113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9010-9010	2.2	11
52	Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9026-9026	2.2	5
51	Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9029-9029	2.2	34
50	Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9075-9075	2.2	1
49	Infectious Colitis Associated With Ipilimumab Therapy. <i>Gastroenterology Research</i> , 2014 , 7, 28-31	1.8	10
48	Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11089-11089	2.2	
47	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4570-4570	2.2	

46	<p> BH2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). <i>Clinical Cancer Research</i>, 2013, 19, 721-30 </p>	12.9	47
45	<p> Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i>, 2013, 8, 479-487 </p>		3
44	<p> Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i>, 2013, 31, 1767-74 </p>	2.2	295
43	<p> BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. <i>Clinical Cancer Research</i>, 2013, 19, 6696-702 </p>	12.9	122
42	<p> A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. <i>Journal of Immunotherapy</i>, 2013, 36, 490-5 </p>	5	22
41	<p> Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. <i>Journal of Clinical Oncology</i>, 2013, 31, CRA9006-CRA9006 </p>	2.2	9
40	<p> Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.. <i>Journal of Clinical Oncology</i>, 2013, 31, CRA9007-CRA9007 </p>	2.2	2
39	<p> OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. <i>Journal of Clinical Oncology</i>, 2013, 31, LBA9008-LBA9008 </p>	2.2	10
38	<p> Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. <i>Journal of Clinical Oncology</i>, 2013, 31, CRA9006-CRA9006 </p>	2.2	34
37	<p> Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. <i>Journal of Clinical Oncology</i>, 2013, 31, CRA9007-CRA9007 </p>	2.2	20
36	<p> OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. <i>Journal of Clinical Oncology</i>, 2013, 31, LBA9008-LBA9008 </p>	2.2	59
35	<p> Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>New England Journal of Medicine</i>, 2012, 367, 1694-703 </p>	59.2	2048
34	<p> Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. <i>New England Journal of Medicine</i>, 2012, 366, 707-14 </p>	59.2	1697
33	<p> Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology, The</i>, 2012, 13, 459-65 </p>	21.7	833
32	<p> RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. <i>New England Journal of Medicine</i>, 2012, 366, 207-15 </p>	59.2	838
31	<p> Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i>, 2012, 13, 1087-95 </p>	21.7	708
30	<p> Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. <i>Memo - Magazine of European Medical Oncology</i>, 2012, 5, 302-308 </p>	0.3	
29	<p> Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. <i>Cancer</i>, 2012, 118, 6055-62 </p>	6.4	37

28	Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. <i>Future Oncology</i> , 2012 , 8, 509-23	3.6	20
27	Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. <i>Oncologist</i> , 2012 , 17, 1534-40	5.7	19
26	Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 3414-27	12.9	29
25	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1628-34	2.2	141
24	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4117-4127	2.2	6
23	Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4506-4506	2.2	3
22	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4545-4545	2.2	4
21	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8501-8501	2.2	16
20	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naïve metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8510-8510	2.2	31
19	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8519-8519	2.2	13
18	Biological challenges of BRAF inhibitor therapy. <i>Molecular Oncology</i> , 2011 , 5, 116-23	7.9	23
17	Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2011 , 33, 1804-8	4.2	16
16	Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 3794-802	12.9	43
15	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. <i>Nature</i> , 2010 , 467, 596-9	50.4	1379
14	A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. <i>Clinical Cancer Research</i> , 2010 , 16, 348-57	12.9	32
13	Inhibition of mutated, activated BRAF in metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 809-19	59.2	2871
12	Targeted molecular therapy in melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010 , 29, 196-201	1.4	36
11	B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. <i>Current Oncology Reports</i> , 2010 , 12, 146-52	6.3	39

10	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. <i>Biochemical Pharmacology</i> , 2010 , 80, 638-46	6	15
9	Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5800-7	2.2	268
8	Combination targeted therapy in advanced renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 2368-75	6.4	39
7	Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. <i>Journal of Immunotherapy</i> , 2009 , 32, 181-5	5	43
6	Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2178-85	2.2	212
5	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist</i> , 2008 , 13, 1001-11	5.7	273
4	Determination of chemically reduced pyrrolbenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. <i>Journal of Mass Spectrometry</i> , 2008 , 43, 42-52	2.2	8
3	Opportunities and obstacles to combination targeted therapy in renal cell cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 764s-769s	12.9	95
2	Molecular targets in melanoma from angiogenesis to apoptosis. <i>Clinical Cancer Research</i> , 2006 , 12, 2376s-2383s	23.8	10
1	A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors		2